Scarica l'app Stockscreener
26.09
1.72%
0.44
Dopo l'orario di chiusura:
26.09
Precedente Chiudi:
$25.65
Aprire:
$25.43
Volume 24 ore:
622.68K
Relative Volume:
2.78
Capitalizzazione di mercato:
$879.16M
Reddito:
-
Utile/perdita netta:
-
Rapporto P/E:
-
EPS:
-
Flusso di cassa netto:
-
1 W Prestazione:
-2.36%
1M Prestazione:
-4.82%
6M Prestazione:
+57.17%
1 anno Prestazione:
+0.00%
Intervallo 1D:
$25.23
$26.69
Intervallo di 1 settimana:
$25.01
$27.66
Portata 52W:
$14.35
$36.37
Arrivent Biopharma Inc Stock (AVBP) Company Profile
Nome
Arrivent Biopharma Inc
Settore
Industria
Telefono
240-780-6356
Indirizzo
18 CAMPUS BLVD., NEWTOWN SQUARE
Confronta AVBP con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
AVBP
Arrivent Biopharma Inc
|
26.09 | 879.16M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.27 | 102.31B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
701.85 | 77.13B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
623.82 | 37.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.44 | 31.66B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.08 | 27.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Arrivent Biopharma Inc Stock (AVBP) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-07-22 | Iniziato | Oppenheimer | Outperform |
| 2024-04-30 | Iniziato | H.C. Wainwright | Buy |
| 2024-02-20 | Iniziato | Citigroup | Buy |
| 2024-02-20 | Iniziato | Goldman | Buy |
| 2024-02-20 | Iniziato | Jefferies | Buy |
Arrivent Biopharma Inc Borsa (AVBP) Ultime notizie
(AVBP) Pivots Trading Plans and Risk Controls - Stock Traders Daily
ArriVent BioPharma, Inc. (NASDAQ:AVBP) Short Interest Up 6.1% in November - MarketBeat
Charles Schwab Investment Management Inc. Buys 122,641 Shares of ArriVent BioPharma, Inc. (NASDAQ:AVBP) - Defense World
BNP Paribas Financial Markets Raises Position in ArriVent BioPharma, Inc. (NASDAQ:AVBP) - Defense World
ArriVent BioPharma, Inc. (NASDAQ:AVBP) Shares Acquired by Charles Schwab Investment Management Inc. - MarketBeat
(AVBP) Investment Analysis - Stock Traders Daily
Fmr LLC Purchases 169,514 Shares of ArriVent BioPharma, Inc. (NASDAQ:AVBP) - MarketBeat
Suvretta Capital Management, LLC Acquires Additional Shares in A - GuruFocus.com
Short Interest in ArriVent BioPharma, Inc. (NASDAQ:AVBP) Decreases By 11.9% - MarketBeat
Suvretta Capital Management LLC Purchases 132,459 Shares of ArriVent BioPharma, Inc. (NASDAQ:AVBP) - MarketBeat
(AVBP) Trading Report - Stock Traders Daily
ArriVent BioPharma Reports Advancements and Q3 2024 Financial Results - MSN
Where are the Opportunities in (AVBP) - Stock Traders Daily
ArriVent Biopharma Inc (AVBP) Stock Price & Chart | Trade Now - Capital.com
ArriVent BioPharma (NASDAQ:AVBP) Receives Buy Rating from HC Wainwright - MarketBeat
ArriVent BioPharma, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
ArriVent BioPharma Reports Third Quarter 2024 Financial Results - The Bakersfield Californian
ArriVent Reports $282.9M Cash Position, Firmonertinib Shows Promise in NSCLC Trial | AVBP Stock News - StockTitan
FMR LLC's Strategic Acquisition of ArriVent BioPharma Inc Shares - GuruFocus.com
(AVBP) On The My Stocks Page - Stock Traders Daily
Discover the 3 Best-Performing Biotech IPO Stocks of 2024 - MSN
AlphaCentric Advisors LLC Cuts Stock Holdings in ArriVent BioPharma, Inc. (NASDAQ:AVBP) - MarketBeat
Long Term Trading Analysis for (AVBP) - Stock Traders Daily
ArriVent BioPharma Reports Strong Second Quarter and Highlights Progress - MSN
ArriVent BioPharma (NASDAQ:AVBP) Reaches New 12-Month HighShould You Buy? - MarketBeat
ArriVent To Present FURTHER Data At The 2024 World Conference On Lung Cancer - RTTNews
When the Price of (AVBP) Talks, People Listen - Stock Traders Daily
ArriVent BioPharma, Inc. (NASDAQ:AVBP) Short Interest Up 80.1% in September - MarketBeat
Octagon Capital Advisors LP Increases Stake in ArriVent BioPharma Inc - Yahoo Finance
(AVBP) Proactive Strategies - Stock Traders Daily
ArriVent BioPharma (NASDAQ:AVBP) Shares Up 6.3% - MarketBeat
Novo Holdings A S Buys 422,860 Shares of ArriVent BioPharma, Inc. (NASDAQ:AVBP) - MarketBeat
ArriVent BioPharma, Inc. (NASDAQ:AVBP) Short Interest Up 13.4% in September - MarketBeat
Short Interest in ArriVent BioPharma, Inc. (NASDAQ:AVBP) Rises By 13.4% - MarketBeat
Regeneron purchases former Quad Graphics site in Saratoga Springs - MSN
How to Take Advantage of moves in (AVBP) - Stock Traders Daily
We Think ArriVent BioPharma (NASDAQ:AVBP) Can Afford To Drive Business Growth - Simply Wall St
Bank of New York Mellon Corp Grows Stake in ArriVent BioPharma, Inc. (NASDAQ:AVBP) - Defense World
ArriVent BioPharma (NASDAQ:AVBP) Stock Price Down 5.6% - MarketBeat
It makes sense and dollars to buy ArriVent BioPharma Inc. (AVBP) stock - SETE News
ArriVent BioPharma, Inc.(NasdaqGM:AVBP) added to S&P Biotechnology Select Industry Index - Marketscreener.com
ArriVent BioPharma (NASDAQ:AVBP) Shares Gap Down to $23.94 - Defense World
Was ArriVent BioPharma Inc. (AVBP)’s session last reading good? - US Post News
Closing Figures: ArriVent BioPharma Inc. (AVBP)’s Positive Finish at 24.20, Up 2.59 - The Dwinnex
ArriVent BioPharma: Bringing A Novel Cancer Drug From China (NASDAQ:AVBP) - Seeking Alpha
ArriVent BioPharma (NASDAQ:AVBP) Price Target Increased to $36.00 by Analysts at Citigroup - Defense World
Citigroup Raises ArriVent BioPharma (NASDAQ:AVBP) Price Target to $36.00 - MarketBeat
ArriVent Targets PACC Mutation Market With EGFR TKI Firmonertinib In Lung Cancer - Scrip
ArriVent BioPharma (NASDAQ:AVBP) Shares Down 4.3% - MarketBeat
Global economic uncertainty takes toll on China’s biotech ecosystem - BioWorld Online
ArriVent BioPharma Unveils Promising Phase 1b Data for Firmonertinib in Treating NSCLC - MyChesCo
Arrivent Biopharma Inc Azioni (AVBP) Dati Finanziari
Non sono disponibili dati finanziari per Arrivent Biopharma Inc (AVBP). Controlla altri titoli per ulteriori informazioni.
Reddito
Reddito netto
Flusso di cassa
EPS
Arrivent Biopharma Inc Azioni (AVBP) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| HILLHOUSE INVESTMENT MANAGEMEN | 10% Owner |
Jan 30 '24 |
Buy |
18.00 |
555,555 |
9,999,990 |
4,484,672 |
| ORBIMED ADVISORS LLC | Director |
Jan 30 '24 |
Buy |
18.00 |
444,444 |
7,999,992 |
1,513,664 |
| GORDON CARL L | Director |
Jan 30 '24 |
Buy |
18.00 |
444,444 |
7,999,992 |
1,513,664 |
| HEALY JAMES | Director |
Jan 30 '24 |
Buy |
18.00 |
444,444 |
7,999,992 |
1,696,752 |
2.88%
2.65%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):